Cargando…

Ponatinib efficiently kills imatinib-resistant chronic eosinophilic leukemia cells harboring gatekeeper mutant T674I FIP1L1-PDGFRα: roles of Mcl-1 and β-catenin

BACKGROUND: T674I FIP1L1-PDGFRα in a subset of chronic eosinophilic leukemia (CEL) is a gatekeeper mutation that is resistant to many tyrosine kinase inhibitors (TKIs) (e.g., imatinib, nilotinib and dasatinib), similar to T315I Bcr-Abl. Therefore, novel TKIs effective against T674I FIP1L1-PDGFRα are...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jin, Yanli, Ding, Ke, Li, Honglin, Xue, Mengzhu, Shi, Xiaoke, Wang, Chengyan, Pan, Jingxuan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3928078/ https://www.ncbi.nlm.nih.gov/pubmed/24472312 http://dx.doi.org/10.1186/1476-4598-13-17

Ejemplares similares

Correction to: Ponatinib efficiently kills imatinib-resistant chronic eosinophilic leukemia cells harboring gatekeeper mutant T674I FIP1L1-PDGFRα: roles of Mcl-1 and β-catenin
por: Jin, Yanli, et al.
Publicado: (2021)

The Conformational Control Inhibitor of Tyrosine Kinases DCC-2036 Is Effective for Imatinib-Resistant Cells Expressing T674I FIP1L1-PDGFRα
por: Shen, Yingying, et al.
Publicado: (2013)

FIP1L1-PDGFRα p.T674I-D842L: A Novel and Ponatinib Resistant Compound Mutation in FIP1L1-PDGFRα Positive Leukemia
por: Lierman, Els, et al.
Publicado: (2019)

Antitumor activity of S116836, a novel tyrosine kinase inhibitor, against imatinib-resistant FIP1L1-PDGFRα-expressing cells
por: Shen, Yingying, et al.
Publicado: (2014)

Durable remission after treatment with very low doses of imatinib for FIP1L1-PDGFRα-positive chronic eosinophilic leukaemia
por: Helbig, Grzegorz, et al.
Publicado: (2011)

PB2172: PREVALENCE OF FIP1L1-PDGFRΑ FUSION IN TUNISIAN PATIENTS WITH HYPEREOSINOPHILIA
por: Torkhani, Nermine, et al.
Publicado: (2023)

Renal thrombotic microangiopathy and FIP1L1/PDGFRα-associated myeloproliferative variant of hypereosinophilic syndrome
por: Langlois, Anne Lyse, et al.
Publicado: (2013)

The oncogenic FIP1L1-PDGFRα fusion protein displays skewed signaling properties compared to its wild-type PDGFRα counterpart
por: Haan, Serge, et al.
Publicado: (2015)

Anthelmintic niclosamide suppresses transcription of BCR-ABL fusion oncogene via disabling Sp1 and induces apoptosis in imatinib-resistant CML cells harboring T315I mutant
por: Jin, Bei, et al.
Publicado: (2018)

The BCR-ABL1 Inhibitors Imatinib and Ponatinib Decrease Plasma Cholesterol and Atherosclerosis, and Nilotinib and Ponatinib Activate Coagulation in a Translational Mouse Model
por: Pouwer, Marianne G., et al.
Publicado: (2018)

Phase 1 Clinical Trial of Trametinib and Ponatinib in Patients With NSCLC Harboring KRAS Mutations
por: Arbour, Kathryn C., et al.
Publicado: (2021)

BIRC6 mediates imatinib resistance independently of Mcl-1
por: Okumu, Denis O., et al.
Publicado: (2017)

Combination of panobinostat with ponatinib synergistically overcomes imatinib‐resistant CML cells
por: Matsuda, Yasufumi, et al.
Publicado: (2016)

Rotating between ponatinib and imatinib temporarily increases the efficacy of imatinib as shown in a chronic myeloid leukaemia model
por: Lindström, H. Jonathan G., et al.
Publicado: (2022)

Loeffler endocarditis in chronic eosinophilic leukemia with FIP1L1/PDGFRA rearrangement: full recovery with low dose imatinib
por: Kim, Dae Sik, et al.
Publicado: (2018)

SAT-674 Anti PD1 Induced Type 1 Diabetes
por: Naranjo, Maria Belen, et al.
Publicado: (2020)

Cardiac Manifestations from Non-FIP1L1-PDGFRα-Associated Hypereosinophilic Syndrome in a 13-Year-Old African American Boy
por: Salm, Cindy M., et al.
Publicado: (2009)

FIP1L1–PDGFRα-Positive Loeffler Endocarditis—A Distinct Cause of Heart Failure in a Young Male: The Role of Multimodal Diagnostic Tools
por: Varga, Andreea, et al.
Publicado: (2023)

Discovery of imatinib-responsive FIP1L1-PDGFRA mutation during refractory acute myeloid leukemia transformation of chronic myelomonocytic leukemia
por: Shah, Shilpan, et al.
Publicado: (2014)

Angioimmunoblastic T-cell lymphoma and hypereosinophilic syndrome with FIP1L1/PDGFRA fusion gene effectively treated with imatinib: A case report
por: Yamamoto, Masayo, et al.
Publicado: (2017)

In Vitro Comparison of the Effects of Imatinib and Ponatinib on Chronic Myeloid Leukemia Progenitor/Stem Cell Features
por: Tusa, Ignazia, et al.
Publicado: (2020)

The Rab11 effectors Fip5 and Fip1 regulate zebrafish intestinal development
por: Jewett, Cayla E., et al.
Publicado: (2020)

Impact of ABCB1 1236C > T-2677G > T-3435C > T polymorphisms on the anti-proliferative activity of imatinib, nilotinib, dasatinib and ponatinib
por: Dessilly, Géraldine, et al.
Publicado: (2016)

Long-term outcomes of imatinib in patients with FIP1L1/PDGFRA associated chronic eosinophilic leukemia: experience of a single center in China
por: Qu, Shi-Qiang, et al.
Publicado: (2016)

Sustained Complete Molecular Remission With Imatinib Monotherapy in a Child Presenting With Blast Phase FIP1L1-PDGFRA-Associated Myeloid Neoplasm With Eosinophilia
por: Jain, Juhi, et al.
Publicado: (2020)

Chitinase-1 Activity in Serum of Cats with FIP
por: Stranieri, Angelica, et al.
Publicado: (2023)

Pristimerin induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation by blocking NF-κB signaling and depleting Bcr-Abl
por: Lu, Zhongzheng, et al.
Publicado: (2010)

LSP1: gatekeeper of the endothelium
por: Van Epps, Heather L.
Publicado: (2005)

P674: 2ND-LINE PONATINIB IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CML-CP) PATIENTS FAILING OR INTOLERANT TO 1ST-LINE 2ND GENERATION TKI THERAPY: INTERIM ANALYSIS OF THE PROSPECTIVE PONS TRIAL
por: Le Coutre, Philipp, et al.
Publicado: (2023)

Sensitivity of imatinib-resistant T315I BCR-ABL CML to a synergistic combination of ponatinib and forskolin treatment
por: Oaxaca, Derrick M., et al.
Publicado: (2016)

S110: PHALLCON: A PHASE 3 STUDY COMPARING PONATINIB VERSUS IMATINIB IN NEWLY DIAGNOSED PH+ ALL
por: Jabbour, Elias, et al.
Publicado: (2023)

Correction to: Pristimerin induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation by blocking NF-κB signaling and depleting Bcr-Abl
por: Lu, Zhongzheng, et al.
Publicado: (2021)

Corrigenda: Revision of the Neotropical green lacewing genus Ungla (Neuroptera, Chrysopidae). ZooKeys 674: 1–188. https://doi.org/10.3897/zookeys.674.11435
por: Tauber, Catherine A., et al.
Publicado: (2017)

Axitinib in Ponatinib-Resistant B-Cell Acute Lymphoblastic Leukemia Harboring a T315L Mutation
por: Giudice, Valentina, et al.
Publicado: (2020)

Chronic eosinophilic leukemia with FIP1L1-PDGFRA rearrangement
por: Kim, Tae Hee, et al.
Publicado: (2016)

Pref-1, a Gatekeeper of Adipogenesis
por: Hudak, Carolyn S., et al.
Publicado: (2013)

PV1: Gatekeeper of Endothelial Permeability
por: Zhao, Yutong, et al.
Publicado: (2020)

Activation of PDGFr-β Signaling Pathway after Imatinib and Radioimmunotherapy Treatment in Experimental Pancreatic Cancer
por: Abe, Michio, et al.
Publicado: (2011)

Runs 662, 669, 674 and 679, MD, R1: RF programs with variable $\Gamma$
por: Ciapala, Edmond, et al.
Publicado: (1976)

LncRNA ZNF674-AS1 regulates granulosa cell glycolysis and proliferation by interacting with ALDOA
por: Li, Duan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_a20vv1qsg2e7cd0hrb366c377t